Sera Prognostics Announces Participation in Upcoming Conferences
Sera Prognostics Inc., known for its commitment to enhancing maternal and neonatal health, is gearing up for a series of important investor conferences. The company, operating under the ticker symbol Nasdaq: SERA, focuses on delivering cutting-edge pregnancy biomarker information that empowers both healthcare providers and patients.
Key Investor Conference Details
Among the significant events, Sera Prognostics has confirmed its participation in two prominent conferences:
William Blair 45th Annual Growth Stock Conference
This event will take place from June 3 to 5. Doug Fisher, M.D., Strategic Advisor to Sera, will hold meetings on June 4 to share insights into the company's vision and initiatives.
Jefferies Global Healthcare Conference
Concurrent with the William Blair conference, Sera will also engage in the Jefferies Global Healthcare Conference. Zhenya Lindgardt, President and CEO, along with CFO Austin Aerts, will partake in meetings and discussions. Lindgardt is set to present on June 4 from 3:10 PM to 3:40 PM ET, offering valuable updates about the company.
For those interested, a live webcast of Lindgardt's presentation will be accessible on the Investors page of the company's official website.
About Sera Prognostics, Inc.
Sera Prognostics is a health diagnostics leader dedicated to improving outcomes for women and newborns through precision pregnancy care. The company's mission centers on delivering critical pregnancy information to enhance maternal and infant health while reducing healthcare costs. With a strong portfolio of diagnostic tests, Sera focuses on early predictions regarding preterm birth risk and other pregnancy complications.
The PreTRM® Test is particularly noteworthy, as it provides vital data to healthcare providers about the risk of spontaneous premature delivery, allowing for timely interventions for women identified at higher risk. This proactive approach is pivotal in improving health outcomes for both mothers and their newborns.
Understanding Preterm Birth
Preterm birth, occurring before 37 weeks of gestation, poses significant health risks for newborns, leading to various complications. Recent statistics reveal that over ten percent of infants are born prematurely in the United States, highlighting a pressing public health challenge. Prematurity is linked to long-term medical issues, including neurological impairments and chronic health conditions, which can lead to substantial healthcare expenditures.
In 2016 alone, the costs associated with managing complications arising from preterm birth were estimated at around $25 billion, emphasizing the critical need for effective early prediction and intervention strategies.
The Role of the PreTRM® Test
The PreTRM® Test stands out as a first-of-its-kind, validated blood-based biomarker test that accurately predicts the risk of preterm birth in asymptomatic pregnancies. By measuring specific proteins in the blood, this test enables healthcare providers to identify which women may experience preterm birth during weeks 18 to 20 of pregnancy, thereby guiding tailored clinical decisions based on individual risk assessments.
Frequently Asked Questions
What is Sera Prognostics known for?
Sera Prognostics is recognized for its innovative work in pregnancy care, providing crucial biomarker information to improve maternal and neonatal health.
What is the PreTRM® Test?
The PreTRM® Test is a blood test that predicts the risk of spontaneous preterm birth, allowing for earlier and more personalized medical interventions.
When will Sera participate in investor conferences?
Sera Prognostics will participate in the William Blair conference from June 3 to 5, and at the Jefferies conference during the same period.
Who will represent Sera at the conferences?
Doug Fisher, M.D., Zhenya Lindgardt, and Austin Aerts will represent Sera Prognostics and engage with investors.
Why is preterm birth a concern?
Preterm birth is a major cause of health issues in newborns, leading to long-term complications and significant healthcare costs.
